Download Files:
Products Details
Product Description
– Dexpramipexole (KNS-760704), also called R-(+)-Pramipexole, is a neuroprotective agent and a weak non-ergot dopamine receptor agonist.
Web ID
– HY-17355B
Shipping
– Room temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C10H17N3S
References
– [1]Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler|[2]Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11.|[3]Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6.|[4]Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011 Aug;51(8):1177-85.|[5]Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13(12):911-20.
CAS Number
– 104632-28-2
Molecular Weight
– 211.33
SMILES
– NC1=NC(CC[C@@H](NCCC)C2)=C2S1
Clinical Information
– Launched
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Dopamine Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
